Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295085 | 0.91 | KMT2A (0.44) | KMT2AALDH1A1ACP3SMN1; SMN2MEN1 | |
| SCHEMBL17290927 | 0.91 | KMT2A (0.44) | KMT2AALDH1A1ACP3SMN1; SMN2MEN1 | |
| SCHEMBL1491141 | 0.87 | MMP8 (0.53) | ALDH1A1ACP3MMP8 | |
| SCHEMBL1653533 | 0.84 | PTGS1 (0.62) | KMT2AALDH1A1ACP3MEN1PTGS1 | |
| SCHEMBL9019965 | 0.84 | KMT2A (0.47) | KMT2AACP3MEN1PTGS1PTGS2 | |
| SCHEMBL29484096 | 0.84 | PTGS1 (0.62) | KMT2AALDH1A1ACP3MEN1PTGS1 | |
| SCHEMBL9432428 | 0.84 | KMT2A (0.47) | KMT2AACP3MEN1PTGS1PTGS2 | |
| SCHEMBL1492817 | 0.84 | PTGS1 (0.62) | KMT2AALDH1A1ACP3MEN1PTGS1 | |
| SCHEMBL5471248 | 0.82 | KMT2A (0.46) | KMT2AALDH1A1ACP3MEN1RAB9A | |
| SCHEMBL10676737 | 0.82 | KMT2A (0.46) | KMT2AALDH1A1ACP3MEN1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110317200-B | Pyrimidinium compounds and uses thereof | 东莞市东阳光农药研发有限公司 | 2020-09-11 | — | — | CN | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | KMT2A 3956/4885ALDH1A1 802/4885ACP3 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.